Spots Global Cancer Trial Database for A Study of ADH-1 in Combination With Normothermic Isolated Limb Infusion of Melphalan
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of ADH-1 in Combination With Normothermic Isolated Limb Infusion of Melphalan
Official Title: An Open-Label, Multicenter, Phase 1/2 Dose Escalation Study to Evaluate Safety, Tolerability and Anti-tumor Activity of Systemic ADH-1 in Combination With Normothermic Isolated Limb Infusion of Melphalan in Subjects With Locally Advanced In-Transit Malignant Melanoma (Adherex Protocol Number AHX-01-007).
Study ID: NCT00421811
Conditions
Study Description
Brief Summary: N-cadherin, a protein involved in blood vessel cell binding and on the surface of many tumor cells, is increased as cancer progresses. ADH-1 blocks N-cadherin. This study will test the safety and effects of the combination ADH-1 with Normothermic Isolated Limb Infusion of Melphalan in subjects with locally advanced malignant melanoma.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of Colorado, Denver, Aurora, Colorado, United States
University of Florida College of Medicine, Gainesville, Florida, United States
H. Lee Moffitt Cancer Center, Tampa, Florida, United States
Duke University Medical Center, Durham, North Carolina, United States
Lehigh Valley Hospital, Allentown, Pennsylvania, United States
MD Anderson Cancer Center, Houston, Texas, United States
Intermountain Medical Center, Murray, Utah, United States
Contact Details
Name: Doug Tyler, MD
Affiliation: Duke University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
